News

KARO PHARMA´S BOARD OF DIRECTORS HAS RESOLVED TO REPURCHASE OWN SHARES

18 June, 2018

The repurchase will be carried out in accordance with the Regulation (EU) No 596/2014 of the European Parliament and the Commission Delegated Regulation (EU) 2016/1052 (the “EU regulations”) and will be managed by Swedbank deciding on trading decisions, independent of Karo Pharma, regarding the timing of the repurchase. The repurchases are subject to the following...

Läs mer

KARO PHARMA’S RIGHTS ISSUE FULLY SUBSCRIBED

01 June, 2018

Karo Pharma’s rights issue, for which the subscription period ended 29 May 2018, was fully subscribed. 53,589,146 shares, corresponding to approximately 97.8 percent of the shares issued, were subscribed for with subscription rights. The remaining 1,188,448 shares, corresponding to approximately 2.2 percent of the shares issued in the rights issue, have been alloted to subscribers...

Läs mer

KARO PHARMA PUBLISHES PROSPECTUS SUPPLEMENT

23 May, 2018

Karo Pharma AB (“Karo Pharma”) has prepared a prospectus supplement, in addition to the prospectus regarding the fully guaranteed rights issue announced on 11 May 2018, which has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus supplement is available on Karo Pharma’s website www.karopharma.se, on SEB’s website www.sebgroup.com/prospectuses and on...

Läs mer

KARO PHARMA RECEIVES MILESTONE PAYMENT FOR RORGAMMA PROJECT FROM PFIZER

21 May, 2018

Pfizer has informed Karo Pharma that a new milestone has been achieved. This means that Karo Pharma receives a payment of 6 MUSD. In December 2011, Karo Pharma entered a research collaboration and licensing agreement with the American company Pfizer. The aim of this agreement is to discover and develop compounds that inhibit the activity...

Läs mer

KARO PHARMA PUBLISHES PROSPECTUS AND INTENTION TO ISSUE BOND

11 May, 2018

Karo Pharma AB’s (“Karo Pharma”) prospectus regarding the fully guaranteed rights issue has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus is available on Karo Pharma’s website www.karopharma.se, on SEB’s website www.sebgroup.com/prospectuses and on Swedbank’s website www.swedbank.se/prospekt. The prospectus sets forth Karo Pharma’s intention to issue bond loans in 2018...

Läs mer

THE TERMS FOR KARO PHARMA’S RIGHTS ISSUE HAVE BEEN DETERMINED

30 April, 2018

The Board of Directors of Karo Pharma AB (“Karo Pharma” or the “Company”) has determined the terms for the Company’s rights issue which was resolved and announced on 4 April 2018. The rights issue is subject to approval by the Annual General Meeting on 3 May 2018. Summary · For each existing share held at...

Läs mer

THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING

04 April, 2018

On 1 March 2018, Karo Pharma AB (”Karo Pharma” or the “Company”) announced the agreement to acquire a product portfolio from the Danish pharmaceutical company LEO Pharma A/S (the ”Acquisition”). The Acquisition is financed by a combination of new loans and a rights issue On 4 April 2018, the Board of Directors resolved on a...

Läs mer

KARO PHARMA SUPPORTS OPERATION SMILE

23 March, 2018

Karo Pharma has decided to support Operation Smile with a donation of 2,5 MSEK. The Chairman of Karo Pharma will make a private donation of the same amount. The total sum of 5 MSEK enables more than 2000 surgeries of children suffering from lip and cleft palate. In addition, the company has decided to donate...

Läs mer

KARO PHARMA ACQUIRES A MAJOR PRODUCT PORTFOLIO

01 March, 2018

· Karo Pharma acquires a product portfolio from the Danish pharmaceutical company LEO Pharma A/S for 260 MEURO, effective from 4th of April 2018. · The turnover of the acquired product portfolio was ca 700 MSEK in 2017. Half of the turnover comes from the Nordics, ca 266 MSEK from the rest of Europe and...

Läs mer

CHANGE IN THE NUMBER OF SHARES AND VOTES IN KARO PHARMA

31 January, 2018

STOCKHOLM 31 January 2018 – As of 31 January 2018, the last trading day of the month, the aggregate number of shares and votes in Karo Pharma AB amounts to 109,555,188. The increase in the number of shares and votes is attributable to the recently completed rights issue of 27,388,797 shares. The rights issue was...

Läs mer